EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis

Background The plasma‐based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results. Aim This meta‐analysis aims to clarify the role of the EGFR‐plasma test in...

Full description

Saved in:
Bibliographic Details
Published in:Cancer reports 2022-08, Vol.5 (8), p.e1544-n/a
Main Authors: Phan, Thang Thanh, Tran, Vinh Thanh, Tran, Bich‐Thu, Ho, Toan Trong, Pho, Suong Phuoc, Le, Anh Tuan, Le, Vu Thuong, Nguyen, Hang Thuy, Nguyen, Son Truong
Format: Article
Language:English
Subjects:
Biopsy
Clinical trials
ctDNA
EGFR
Ethnicity
Lung cancer
Medical prognosis
Meta-analysis
Mutation
NSCLC
Original
Patients
Plasma
prognosis
Survival analysis
White people
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The plasma‐based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results. Aim This meta‐analysis aims to clarify the role of the EGFR‐plasma test in prognosis for non‐small cell lung cancer (NSCLC) who have mutant tumors and receive EGFR tyrosine kinase inhibitors (TKIs). Methods and Results The PubMed/MEDLINE, Web of Science, Cochrane Library, and Google Scholar databases were searched for relevant studies by April 10, 2021. The hazard ratio (HR) from reports was extracted and used to assess the correlation of EGFR‐plasma status with progression‐free survival (PFS) and overall survival (OS). A total of 35 eligible studies with 4106 patients were enrolled in the final analysis. Patients with concurrent EGFR mutations in pretreatment plasma have shorter PFS (HR = 2.00, 95% confidence interval [CI]: 1.73–2.31, p 
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.1544